This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
STELARA® (ustekinumab)
Medical Information
Use of Subcutaneous Formulation of STELARA as Induction Treatment in Ulcerative Colitis
Last Updated: 04/08/2026
SUMMARY
- The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
- Please refer to the local labeling for relevant information on dosage and administration for STELARA.
- The phase 3 clinical trial program of STELARA in the treatment of ulcerative colitis (UC) did not evaluate the use of subcutaneous (SC) formulation as induction therapy.1
Literature Search
A literature search of MEDLINE®
References
| 1 | Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. |
Would you like to clear and leave your conversation? Message history will be lost.